Skip to Content
Merck

A versatile drug delivery system targeting senescent cells.

EMBO molecular medicine (2018-07-18)
Daniel Muñoz-Espín, Miguel Rovira, Irene Galiana, Cristina Giménez, Beatriz Lozano-Torres, Marta Paez-Ribes, Susana Llanos, Selim Chaib, Maribel Muñoz-Martín, Alvaro C Ucero, Guillermo Garaulet, Francisca Mulero, Stephen G Dann, Todd VanArsdale, David J Shields, Andrea Bernardos, José Ramón Murguía, Ramón Martínez-Máñez, Manuel Serrano
ABSTRACT

Senescent cells accumulate in multiple aging-associated diseases, and eliminating these cells has recently emerged as a promising therapeutic approach. Here, we take advantage of the high lysosomal β-galactosidase activity of senescent cells to design a drug delivery system based on the encapsulation of drugs with galacto-oligosaccharides. We show that gal-encapsulated fluorophores are preferentially released within senescent cells in mice. In a model of chemotherapy-induced senescence, gal-encapsulated cytotoxic drugs target senescent tumor cells and improve tumor xenograft regression in combination with palbociclib. Moreover, in a model of pulmonary fibrosis in mice, gal-encapsulated cytotoxics target senescent cells, reducing collagen deposition and restoring pulmonary function. Finally, gal-encapsulation reduces the toxic side effects of the cytotoxic drugs. Drug delivery into senescent cells opens new diagnostic and therapeutic applications for senescence-associated disorders.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
(3-Aminopropyl)triethoxysilane, 99%
Sigma-Aldrich
Anti-γ-Tubulin antibody, Mouse monoclonal, clone GTU-88, ascites fluid
Sigma-Aldrich
β-Galactosidase from Aspergillus oryzae, ≥8.0 units/mg solid
Sigma-Aldrich
Wheaton sample vials with rubber lined caps, clear glass vial, volume 8 mL, thread for 15-425